Harvest Fund reduced its stake in REMEGEN (09995) by 160,000 shares, with a price of approximately 84.83 Hong Kong dollars per share.
On May 19th, Fuhui Fund reduced its holdings of Rongchang Biology (09995) by 160,000 shares, with a price of 84.8306 Hong Kong dollars per share, for a total amount of approximately 135.729 million Hong Kong dollars.
According to the latest information from the Hong Kong Stock Exchange, on May 19th, the Hang Seng Index Fund reduced its holdings of REMEGEN (09995) by 160,000 shares, with a price of HK$84.8306 per share, totaling approximately HK$13.5729 million. After the reduction, the latest number of shares held is 10.3745 million, with a new shareholding ratio of 4.97%.
Related Articles
New IPO news: Xiangdao Travel submitted a second application to the Hong Kong Stock Exchange, attracting key industry chain investors such as Momenta, Gaode, and Contemporary Amperex Technology.
New Stock News | Innovative biopharmaceutical company Sinocelltech Inc. (688520.SH) files for listing on the Hong Kong Stock Exchange with a gross profit margin of over 90% for three consecutive years.
New stock news | EROAD Travel's secondary listing on the Hong Kong Stock Exchange
New IPO news: Xiangdao Travel submitted a second application to the Hong Kong Stock Exchange, attracting key industry chain investors such as Momenta, Gaode, and Contemporary Amperex Technology.
New Stock News | Innovative biopharmaceutical company Sinocelltech Inc. (688520.SH) files for listing on the Hong Kong Stock Exchange with a gross profit margin of over 90% for three consecutive years.
New stock news | EROAD Travel's secondary listing on the Hong Kong Stock Exchange
